Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calderasib + Pembrolizumab in First-line KRAS G12C-Mutant, PD-L1 ≥50% Advanced NSCLC
NCT06345729Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of calderasib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started May 2024; status: recruiting.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06345729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345729.